Sangamo Therapeutics, Inc.
SGMOSangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Richmond, California, that develops cell and gene therapies for severe genetic diseases.
Drugs in Pipeline
9
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SGMO's past catalysts played out
Plerixafor
Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin
Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery
Alzheimer's Disease
TX200-TR101
Kidney Transplant Rejection
ST-920
Fabry Disease
SB-728-T
HIV
Cyclophosphamide
Human Immunodeficiency Virus (HIV)
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])
Idiopathic Parkinson's Disease
SB-509
Diabetes Mellitus, Type 1
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Plerixafor | Phase 2 | Sickle Cell Disease | - | - |
CERE-120: Adeno-Associated Virus Delivery of Neurturin | Phase 2 | Idiopathic Parkinson's Disease | - | - |
CERE-110: Adeno-Associated Virus injection Surgery | Phase 2 | Alzheimer's Disease | - | - |
TX200-TR101 | Phase 2 | Kidney Transplant Rejection | - | - |
ST-920 | Phase 2 | Fabry Disease | - | - |
SB-728-T | Phase 2 | HIV | - | - |
Cyclophosphamide | Phase 2 | Human Immunodeficiency Virus (HIV) | - | - |
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) | Phase 2 | Idiopathic Parkinson's Disease | - | - |
SB-509 | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
Frequently asked questions
What is in Sangamo Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Sangamo Therapeutics, Inc.'s (SGMO) pipeline across Phase 2. Its lead program is Plerixafor (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sangamo Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Sangamo Therapeutics, Inc. (SGMO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SGMO biotech catalysts?→
Add SGMO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sangamo Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.